0001193125-23-242058.txt : 20230926 0001193125-23-242058.hdr.sgml : 20230926 20230926091328 ACCESSION NUMBER: 0001193125-23-242058 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230926 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230926 DATE AS OF CHANGE: 20230926 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tivic Health Systems, Inc. CENTRAL INDEX KEY: 0001787740 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 814016391 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41052 FILM NUMBER: 231277478 BUSINESS ADDRESS: STREET 1: 25821 INDUSTRIAL BLVD., SUITE 100 CITY: HAYWARD STATE: CA ZIP: 94545 BUSINESS PHONE: (888)276-6888 MAIL ADDRESS: STREET 1: 25821 INDUSTRIAL BLVD., SUITE 100 CITY: HAYWARD STATE: CA ZIP: 94545 8-K 1 d473434d8k.htm 8-K 8-K
false 0001787740 0001787740 2023-09-26 2023-09-26

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 26, 2023

 

 

Tivic Health Systems, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-41052   81-4016391
(State or Other Jurisdiction
of Incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

25821 Industrial Blvd.,

Suite 100

  
Hayward, California   94545
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: 888 276-6888

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, par value $0.0001 per share   TIVC   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 7.01 Regulation FD Disclosure.

On September 26, 2023, Tivic Health Systems, Inc. (the “Company”) issued a press release announcing that the Company entered into an agreement with InStep health. A copy of that press release is furnished as Exhibit 99.1 to this Current Report, and is incorporated herein by reference.

The information set forth under Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.

Forward-Looking Statements

This Current Report, including Exhibit 99.1 attached hereto, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms “anticipates,” “expects,” “estimates,” “believes,” “will” and similar expressions, as they relate to us or our management, are intended to identify such forward-looking statements.

Forward-looking statements in this Current Report, including Exhibit 99.1 attached hereto, or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission, reports to the stockholders of the Company and other publicly available statements issued or released by us involve known and unknown risks, uncertainties and other factors which could cause our actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon management’s best estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Securities and Exchange Commission, each of which could adversely affect our business and the accuracy of the forward-looking statements contained herein.

Item 9.01 Financial Statements and Exhibits.

 

  (d)

Exhibits.

 

Exhibit

   

Description

99.1    Press Release, dated September 26, 2023.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      TIVIC HEALTH SYSTEMS, INC.
Date: September 26, 2023     By:  

/s/ Jennifer Ernst

      Name: Jennifer Ernst
Title: Chief Executive Officer
 EX-99.1 2 d473434dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Tivic Health Partners with InStep Health to Access over 2,500 Healthcare

Providers and their Patients

New Healthcare Provider Program Set to Educate and

Drive Patient Awareness of ClearUP

SAN FRANCISCO – September 26, 2023 – Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that it has signed an agreement with InStep Health® to introduce the Company’s bioelectronic sinus device, ClearUP®, to over 2,500 healthcare providers (HCP) and their patients.

InStep Health assists pharmaceutical, OTC, and consumer-packaged brands to reach consumers at the center of care, whether in the doctor’s office, pharmacy, or within the store aisles. The company offers a fully integrated messaging platform that combines offline tactile and online digital media activation with access to over 250,000 HCPs, working in more than 177,000 offices, and exclusive programs in 40,000+ chain and community pharmacies nationwide.

Tivic’s program with InStep Health will reach allergists, ENTs, and primary care providers through in-office provider education kits, provider 1:1 email campaigns, and digital advertising. The 4-month program will run from November 2023 until February 2024 with the goals of educating HCPs and driving patient awareness of ClearUP during allergy, cold, and flu seasons.

“The InStep Health program is a cost-effective way to reach key physicians who are highly influential in the buying decision for patients with allergic rhinitis, sinus infections, head pain, and congestion,” says Jennifer Ernst, CEO of Tivic. “We’re looking forward to launching the program as an important step to grow the medical community’s awareness, provide education, and increase HCP recommendations and sales.”

Tivic ClearUP’s non-invasive and targeted approach to the treatment of inflammatory health conditions gives consumers a preferred drug-free, FDA approved, and clinically proven solution compared to their current allergy and sinus treatments.

About Tivic

Tivic is a commercial health tech company advancing the field of bioelectronic medicine. Tivic’s patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures. Tivic’s non-invasive and targeted approach to the treatment of inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic’s first commercial product, ClearUP, is an FDA approved, award-winning, handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and is available through online retailers and commercial distributors. For more information visit http://tivichealth.com @TivicHealth

Forward-Looking Statements

This press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the issuance of the new patent by the USPTO; clinical trial results; FDA approval of any product developed based on the filed patent; market and other conditions; supply chain constraints; macroeconomic factors, including inflation; and unexpected costs, charges, or expenses that reduce Tivic’s capital resources. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Tivic’s actual results to differ from those contained in the forward-looking statements, see Tivic’s filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 31, 2023, under the heading “Risk Factors”; as well as the company’s subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.

Media Contact:

Kayleigh Westerfield

Kayleigh.Westerfield@tivichealth.com

Investor Contact:

Hanover International, Inc.

ir@tivichealth.com

EX-101.SCH 3 tivc-20230926.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 tivc-20230926_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 tivc-20230926_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g473434snap4nn.jpg GRAPHIC begin 644 g473434snap4nn.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Sep. 26, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001787740
Document Type 8-K
Document Period End Date Sep. 26, 2023
Entity Registrant Name Tivic Health Systems, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-41052
Entity Tax Identification Number 81-4016391
Entity Address, Address Line One 25821 Industrial Blvd.
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Hayward
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94545
City Area Code 888
Local Phone Number 276-6888
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol TIVC
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
XML 8 d473434d8k_htm.xml IDEA: XBRL DOCUMENT 0001787740 2023-09-26 2023-09-26 false 0001787740 8-K 2023-09-26 Tivic Health Systems, Inc. DE 001-41052 81-4016391 25821 Industrial Blvd. Suite 100 Hayward CA 94545 888 276-6888 false false false false Common Stock, par value $0.0001 per share TIVC NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.tivichealthsystems.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d473434d8k.htm tivc-20230926.xsd tivc-20230926_lab.xml tivc-20230926_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d473434d8k.htm": { "nsprefix": "tivc", "nsuri": "http://www.tivichealthsystems.com/20230926", "dts": { "inline": { "local": [ "d473434d8k.htm" ] }, "schema": { "local": [ "tivc-20230926.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] }, "labelLink": { "local": [ "tivc-20230926_lab.xml" ] }, "presentationLink": { "local": [ "tivc-20230926_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2022": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "report": { "R1": { "role": "http://www.tivichealthsystems.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2023-09-26_to_2023-09-26", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d473434d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2023-09-26_to_2023-09-26", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d473434d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.tivichealthsystems.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://www.tivichealthsystems.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://www.tivichealthsystems.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.tivichealthsystems.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://www.tivichealthsystems.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://www.tivichealthsystems.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.tivichealthsystems.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://www.tivichealthsystems.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.tivichealthsystems.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://www.tivichealthsystems.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://www.tivichealthsystems.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.tivichealthsystems.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://www.tivichealthsystems.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://www.tivichealthsystems.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.tivichealthsystems.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.tivichealthsystems.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.tivichealthsystems.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.tivichealthsystems.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.tivichealthsystems.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://www.tivichealthsystems.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.tivichealthsystems.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.tivichealthsystems.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.tivichealthsystems.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://www.tivichealthsystems.com//20230926/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001193125-23-242058-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-242058-xbrl.zip M4$L#!!0 ( *U).E>;L$JF,Q$ #MG . 9#0W,S0S-&0X:RYH=&WM M7>EOXS86_UZ@_P/A;A<9P'>__Z M?8^D9,E';"?.,6T&:,<2[_=^[R2I.?YA//+(/1.2!_Y)KE(LYPCSG<#E_NU) M+E*#PF&._'#Z[3?'0P45H;(O&R[C)[FA4F&C5!KWA5>4S"G>!O& MC'IJ*"=2L9$L.L$(5[%;KE?WDQE)OF@^,$:E]/N7RRYT,:(%[DM%?2<9+5)B MZ=SJ)2B-*W(9U*J5@T<68FLD#<;+ZE:@K@_+9K__V+F<5E>+ZT^KEI2@OAP$ M8D050 =[VBN4JX4I#:"3 @ CTU$,E%7]'!9V*PDM87#^V%)GJ(BE[@Q ;>7] MDBFT59=#!L&>TZAGU,6_%5<>.STL_'Q<,C_AW8@I2K"' OLSXO3K)*396)=TC*6&[DNV4$'+<#]S)Z;'+[XE4$X^=Y%PN0X].4!98 M[I0<\W$#JS-A?W/79;[Y#56NC" 0GXZP+>.-LQ'S7?A/77CTUDYBK#IL ,61 MT#3^ ]%:*->!5W^H(/64.QU03[+C4J;SN<&X>Y+[K.?Q!XSX1\L'BDR:,*2@ M7MMWV?AG-LFEIK2DPH93*X/L'!P>'-3*\_,KS5!&L $3H,:8A&>4Z8;4$@=C M$:T.&JA*3G*2CT(/@:/?#05.!46^$,MS<2S=N)@*1P3(HK6UQPOHI=/C4G8] M=O69%>MG&43"/&H!:EAR:^ZM0>ZX&=/,2QZYBR\&G FBI\ 6BG>S_7.68;.- M<=8+^P^!HX&;/()D"W5.%3N=SBUN.2V;SM5=4C.PN,?]HU1=CPW4T8B*6^X7\'># MT$@%\1O!;X?V%787QIVATBP,F2X%4QTF7:@@;*0>^X%2P4B_Z0<"IAZ_J81C M(@./N^2[LOZ3._WG=Y7]\M%Q*5PVT.[J@:I/'BC5;0TZ(?,+( -@34'R_[%& MY3!Y'M 1]R:-'A\Q2:[8 ^D$(^H?Z;(',^]^X+E'"]CSRU6[USHGW=Y9K]5= M/IWR*TVGVVK^TFGWVJTN.;LZ)ZW?FY_/KGYJD>;UER_M;K=]??6L.5:W,:A*ABYG[J;%:(=QHMZAEO*5--0,Q4=Q)#B*_A@L=C*#YT*63 M"PWKE MSI3>,Z&X0SU+7K/BA35M/]4-^HGGO+C);(?P/SMW$5<)Z2TK] 6C=YC&A,B^ M0>\#@,A&E,O-C$M2<"(9/#4TDLC,6@ 4,$/@LY\!3TI\5ZHMT#"! .I]5-7 M@=5J!I&OQ*09N,^R@)C[Q!R%8J$([G%8-('GS*,/8 WGE1JN8@,8Q*"?J_\& M-+S@'H,R,.Q/R.I5"K5*>:_ZER)(CX[;-M?E: H\D3J'0)QR97^W7GF,/"\A MG8>O(YP[6N+0^;\&GUN0?X'++5VNHX+COB E],8S(OKI?0-CIQF,1ES*9/XH M&\2P_[U/O=WIDM8H](()$V;R61"3JZ#X:0YX\#^TN']G"[Y7WK+EK1U^%9;W M;;WP%3KXS'4%D]+^=0E^<&5C_5O=.ZQ60/^X$?CWG'KD1^_>G0M(\AM%))5W M08OJQK3H1APT-8C(HGAL"RIMH<9ZSR*0..3/VZOM_57=.TLAS)+<"( 7#T&)ML;,B12_9^1Z +X%D^_=,0+6$N3M6L[/ MAIG@K:C_:0;JG]^!Q3HXDJ3'/!8. S]V/G4NS8O0?2)G@!R]H$+CJ$,ETI,L V'WUBE%0]V"_L+QARFPFW)[)W*WMY.Q>@8B$XNM+Y M1D'LHY6M/.$#S#'ZM\PE753AY))*97<%/K*.+[,UMTILP>P-F7.G=Y)H".8P M!/\1_*=^,"9]Y@4/R#4L1&:2P\+/9, ]E$TN"<=S8RYP4P5$\E'D*>JS()+> MA$B0!3F8Z):V0= '.ICXS.YA9SU@C:\.O[HX5F8ID&^TUP!2S#T#_R;; L MG^U(]8/ ZU-@EP+0()7K![7:T;R26\N33K&79#E*GFVA9HXUY4XM/8 :8*0 M,+7SVXD )+7JGD7HS(8K[K/N5 Y(\Z)#JKOE(E3\E(09J[,.'[!="[9=T*X. M$-R__0*J">/;OS%FI\2 K@TUY@%;J=%"I9K";.9D0(+86KEH:GZ =NN@O1$, M]2P>==4GF-!2"H@C-O<;_T+@!:(4G!155FK>2LTM5'?ZG]:#LJG[ >:7!G-; MRHB)#T@_#=*[K%#;<=:#M*V[&M);#PM27H[QTYD 3S]<="A."ZCUVV$%R]WT MKV"7Y?#CF,3K9>K6B*67K';(%2L@'ACHAP=!-]GDF=G8V$KJHX=WK)=F5/\FF4,6LU[/D#GX!4 MP.NIMLX:C7>X,[4B[#,6:%*I]K5X;9QO19<%R-)5@7.7)R$5Y)YZ$2/_*!?Q MSA<)\7+8<.$AIS?*[R\CA146(R:;'UEM_]I\]TN,N1W[0D\YG#OG5J*(Q-M[ M/?!.KJATZ9\&$>0+%7=,D@4\>0+,0BWPN83\$I#$/(@! FA_H M>""23-<"&MEM ;PQSW6,8*ZQ(DWT6-X$!W_@,#3RPX?Y08E@]UQ".\ O]1U, M;%''P4.N6!GOSKM4N-)L"+C+@I'='9H$(VE<%E=R?=Q+YFNNE[Q:5+LL7%KG MXNP:%V._XANX9OO+;H)]^PW8GX6BP49SDH&O4DY.GP%SP,GQ'NA$HA<'G>-G M$Q*'""+%0#2^J^L_1_&"PG$F)5.RDWA\@W&[UZJ__>;UCJ^!?E!LA'OSY]1"@ORCH+.K[H&0PLP!*@RJM.6Q3 MHCFJC2GH&%"<]%8PD^;1RJOM=Q4+B?G.2I&<@<(([18F=)0=!@S?(!(^ET.< M QK-(>]S1>KU8@4UF#:-S4@([-ULBN=A2-?LM,8GBZ$M. 4,C#MHZ.1C"H]Q M8SMV [TG[B>?/R$2/"=X AJ8-!;BAFC$Q%9^=BD\.=:163E5"H(9NRP5Y'&Y M?8;54M0"*H"C[GG:U/09^#C !#?F\X![S+5\DCA^C(V+$TIM*58V#ET7@%Z*P]@/TB,NK_%P8U/&7$X[3//3,4]"XCB-&D MF521S))57\5Z&B7S61)E()/&2HSE2;PQOW1GT_J':5KHI!9L;%8E5-$3.7/ :U(/4X(AMK^<'#! G6H!]IKJTYF069 M/JCM!H[S_&7%A3D7@ M4$9EPC,8.0:K@35DE.JCLGOX(DI^_AR9_MW@"A;MY$XO H$G-0N707"'"-%' M+U'K29*<+'M1Y;^ ?^LK$'3:*/0HN[Z16/& :3#\H%T7RVY#YZ.K&>CBO(0. &()0,9F/U9(M M E"#Z,^_EHJ/%M7O,X^S^_GW".;XE=:.' A)12PTN/.@Q1;FAJ+GH4NO772M MJB(!'/)!!)$(4$^PS%D>^_F;6#*74N_EK<[%US2;3),3[ C.)$;B3*<7K))F^OMR=*1F(. M8@CBR(2,C5+L=6 ?2R>1IH%Q:'3HI)T,K>DCF2#ZS@\>?(MB\UOC.I\%=6J\ M 754 !,RJ40(OCR7.!0C.P0-%$8H&TQ&'H 8HSJM%E$)[TRC-H08%%&,VW3R M "B/*+8B%X!.Q$U#,A#!R!SVBA2XE,_LUT+?T ._E\4-.5:"N*LK9*:@1:*O M"1J%H*6GTI*<6^WK#Q?$:L_1&D;#VV>A5V>< M8:II8% 7O\>(-HT"/]%A (ST(PD1H9RN&6)XB)R=U,F^I3)M-7>B6]_ -*;B MGSKZ8!<)^E)&T%!):Y=Y);B5[4[;UX_7G?-6I]"\OKP\N^FV&O&/]WZZX)&L ML;V)MO M$_3W)F9UU_9&7:/EWV;G;_LRAX-Y<-MX.;-?;!,1MB]\+M#]=0 M(7Y:9]=ZR8:Y*:SOOO*N]=H[SC$B%YPK7PMX:^Q!DO@KF^8[I(6^!T[#1KN* M"])3%K-/V6I=*M5?Q4X^?M5 .H*'^M9V1EZG.%X@KO,8B:\,8,D":J2*P::A MP ),JJ]\37!>-RXD-GK'6X/!PAT_2LP'2]W:P6YMM^:R<;U>*0[52!^> D^A M8YS7/'%ULF))V@]5+%U*PK\+NRKEVHMRJQG 6W*#Z9DVJ@MP^?$"W#E5E.A/ M!.P@:US7^H\Z"L.JJ)X(?BV\J7HE!Q)_3G+Z6NH_$_IO<2^^V?[HZ MZ_W2:75?/(Y/?TO/;"3J')GQIM?-R"[8@70C"#YT?.J:;("PN3B=>I.P6@P' M?0(>&KP84F^ $2%VI).>M@(&&Q$F175WP)QA(&!A[LNX]F_MPBUTVF8<^+W8 MY]K$C7O\2Q$;]?C8*<;M3VTOXV'.NP*OH>\?6?:\6?BRXC#$AH:V)$OD7\SW.>976\*7ZM4/@?Z5U,_+ MH ^/-C9FV$3,*5Y]T+5!FD/.!G/?GQ#K.M3')?//=>A_S./T_U!+ P04 M" "M23I7;OC0\^E?OS9NM MW<%V^!7KV]4&,7AW?OB'>/=^='YZ?OFV\^ED/#GJB*O)'Z=';SNI-JJ7*#U/ M?/\LMYE,.T.QN8'W1\IX98>#P_'O]>:ECGW2?[WU0IN.D*F>&QR@9K[#UUS4 MVS)IY]KT?%[T=PJ_+ZK?I[GW>1:69KGQ/:?_4OW=F]]G,M/IJC_1F7+B3"W% M99Y)W'1P.GY_]K9CR/0ET5/M!7DL!MOOAH/MB^&: 6NG/\/IM^RY M8TYG^).9NF*?3H'C#_EQSWL4*+PQ_O!>7%V.WG;F>Z^>[SW?\9L?2[F M9/WD;>?T_/UYB%+;TK4KV-2GBE7$R>-@3?1"1^)$R=0GXD):;Y1U8JGQV]A< M>574SWPN#J)(.2?RA;+B6??%SD[U+))6-8%^)$3?P/P+FR]T3"9+$PL/J%IX MX35VN*^9]/+;F$0/U^)26T@_S*W,Q)7R%,RCN(RD5VSW_\;00ZL7JHZ6.%C" M6L/YG8E1JJ3]>'%?]3PU)LF2JX.SS8WCRX.ST?AJ=,Z7TKW\GU!\/_VP^V)G M'[$KO,JFRMZWY]G+KGBV\^QY^]E@W#IBL#WF)V+PL87]P?;'(98&5Q_OX8E7 M+W[<%T"]UY%,>TQM?00 S'$?BI6%U@+A:.9CHNBB?:(L6Q<^X>>_5/M]& M/[[>[P:+SJ2+Y9_]S8W)^/?1+UTA15+5FHH2$>59(Q&JATKP(,,>3 M3-E(PY"_$,NISE6J(F]S WL(M(WCC,E+$ZDXW.;S6%:G@1P3Z82#'RK& M/B'G5JF,8'"W\O]^2 CFVL N0%U1<8I1\(FB\'+?;6ZT37?:E(YY5O% MK$S3%>5<@>H\3(3+3B)*84(.5;260(+R.OTT"'N>&E6,^U MERDC6@IZOD!R[0QUI=(':6^;VFBZ%Y1D9C3N-V'WUBK<$ M1UV(JOH2I:4#$<+O0-".WMKCT_XAHD3BM[KH2J/]JLZ0AO6+P45O?NGHESI-*T#(-%6X%+#JBJ.S2>5R835L63$FV.NJ%'QB\W*>B,'Q M^=FD$76)]JKG@#G5-_G22M08O @Q'&S3UF%33D)Q4Z,<76NZM'FPV]\5*I,Z MQ:W #,JU,J9.LHRYFD$!\X"MKUJQU\L0KF3-ABHBY'YIQ,SFF3@#.*A?<&,0 MI0'&T&G4U)84 2SNA1 2ON>Y3+G[55X /X2F8"9Z):.XZI;ROFX9EY;VA*BC M?*(\C8.7L[043DF' OWV0*G:#3QJ :,!N-!4JE'N?$^A<*FNE%A2;ZB)Y%H1 MRE<.C40:J,$D%\2:"20VES?<01#0?VHFF98K\CQ6$3*([*/0&R:MRC5 ,1(6 M=**1Z&Y%]SB-3,@)$&!HP!,5US#>7#EZU@U]4SBY1F*M$8$UHDZ^NX2,JUT%F16R^19$?! MP^ZYS9>\D7LKO&ZXH"['!@X-Y&]*(?BB3838.D600I2YA9N8-P2$.4FT6OGY MS7M/D#X5<&LOOEIR)C<];1:2^+*N.VZ=L$81W@$U>-L+E:RJ81<# M&O\[* "-5:K:>5'9G;304H%6W9OBZ.O>5 &"JB]3%)O#(#W8+NB2DTMQ-?XW M0OZ\4Y_+PWC_AS?\3T=\&A].3MYV=G=V?FR$_ B$?G3Y?S>.D^0^F.:E#_7X M/4:;"LP5J]72^%XMC2XC3537_4RK-"9DWJ^@MT2[Y4+0& (YG6CR- =X&E&3 M0I];9!JBVNNL3$,3S)D=-S>\U7.5:4-ZSJU@"E8A[P)Z%W(.\&'L7I#$LF7D M2\L":_WR[UF:41+B\$")KLM,5A.U?FAJ% Y#9 9B.6CH7L/H-2?1]0OH'3E-5:.L*F%KE<>3 M.H!K7L20:E9/2YP(CX_11%F](COT[8TAM4"#]32\)MX7_>UM3V$)F=K"23QP M_LJQJN3@8ZWD]1,5_''HK+W3JM->>=1*UOH&DQBTQ2 MG\WDBIN))P$?1$$E 'JU('"-F57;Y=&$E(XKIY^!!ZH5_.A(#5!^"*$A:317 M6SH:&@>I.H#FO#D-@Q./63QUW"Q3H<%.))=%Q$P27BL+51RDU!TWR)J'[6:0 MK#_;W%B[[VMG(T1B"GC%).9 ABB$%7-#B8>5!"&K>62.AE=S:J+P7RT%ZC\=+4;V]NA$6GU'5[ M&[R[M4!?B-M+,,W<6LE]D+:WEBTUA=MOV_SS'>L"X;;7I,[:"RZY&P :7&ZM MK&_*+:?&J+EDP9[/F&:1J9 F/ ^H%L!V5-5, 49'*6/H]@JH:- M6#O]#L[6]Q-$I\ 3#>ZB]3VY]2VLYNY:@(74KBG@6X6G#;RAC:U: ^5R%0:6 ME0Z=J A'-,4;:QI.RY1/J1('!TI+X4'%A<,>BT#+H_4[)']PF)74H@7@3IOY M7BHE"BWW!=J#NI(17,69H ?T=*(/Y6 5!1AY93.1+L*\U=Q4>&)%GIQJERZ4 MR^;&@^;RV%*=356[D%;G:&#$+^@C71H]TC+FCD<=F+19"HR$T/<951H^0AAQ MU0>4+2N]4U/"QZN+R?E^TP(A'_2-1_MK?1:K.(3$5M63ZV^71"]U3(/Z2E5< MW<)-X%KY\/F'\L3<7>D.S'TEM,"J^AI#^L-;PH.C]R*;H_F:/ /N[OH6DC(O_WFD:. M4"T/=(BN6.4EPRJ2+(9P/<&% )I"QF%W7$(W@9EUR(,)O/L5ZD?BH1FBDLN< MXAXHX$$KFO"N3;E-S,*7/$S[FA4S8136NEL!D&TLPX,*R ^AEW/]H!L0Q"08 M;ZD[H&SN;K[,7!V-6C#6N/C &++C4I$?%*]CTN%?U9=2J<*Y]#F#O UL?HFD MB.,0[,#I0"0&WJ4"'1.Q)"H<%;4^DK, 47_2!Y=[ _,H-?\WZB*3L:+[N?2Q M(Z8FS$AYF,N#DUY>TS=0(*#T_/6H+.CE@-QUT:J^1*I@HK+P1%M6&IL;E< G MA9S*)0W=X\?^VO14:O4#?T\>46@BW_\>"O4WB:D>ZF-SXQ-DCK)A\'SXTJ<9 MQ#\V]VZM7?OKK8E!\!^NOL.0,#88'@'^[QKY$VGXSP-C^CP2OM;3$,X8_L9_ MK:8$:/M8N._YNH20G!_^@47^OSC^ U!+ P04 " "M23I7-&AK[T4# !J M"P $0 '1I=F,M,C R,S Y,C8N>'-DO5;?;]LV$'XOT/_AJJ<-F$1+:8): MB%-D2P,$2+/!38>]%;1TMHE1I$922?S?[TA)CNS$KIL,\XMIWGUWW_VD3S\^ M5!+NT%BAU21*DU$$J I="K681(V-N2V$B#Z>O7US^BZ.X>+RZ@9B6#I7VYRQ M^_O[I)P+9;5L'%FP2:$K!G'9D8FVBQ8Z0QSJQH9*<6DA484T0#Z?=P3 M#!7"2^P:..=V%D"]Q*#R<;C8X8M8:CC., (H7Z>P_"BV?4)4,G3R#W1P&0 MCL=C%J1;E$JW&4%G_9BUPJ#-G3-BUCB\U*:ZP#EO)*$:]4_#I9@++(,6M6R% MRFWH;&HX;A;H;GB%MN8%OC#IU&3/14BD4_;7Y^LOH?^B,P\ ""TIJEH;!VUG M7NLB#,R>Q/I?<5^/V%_%:18?I0D9BT ]RW]',8&]FDA?YA<16??(P43LKE[V MA]@?=GE_?@)>G('M(??QCWW\Z7A/%1=$NLO9X M>%T>D:_JS7X_^#P<[W6\O5 ZK\$G5TJ[X&C(A->U4'/=7=&E;^*\[^0ISB$L MLIR;PFB)^]<=JXVNT3A!B_]Q&%H#2X/S2>3W?]SOF6^2SQ+:,[W*$P>;X^7% MC" HKQ_I]5@GG =?>S%X.;V@7*Y-^W:81);R+@?C^3^'6QO\T7 )8FG/A[+M MCOJ/@=8/!^_]W)(&^,/7Z=4A+\7ZJ6"./VBEJU5+]T(7C7^7^N]S57Y21')U M13UFJD P D%ORI34OQVDOJ;;$RZ1_MJ)T,CIR'_HGU]O87CDJH36' SLG;)M M(]OV&XOE[^HLG LNBT:NT]^!.XU]P.W"'8Y\9+8;U]WVI>L'FFU/='Y7>:;JP8 *1) 5 =&EV8RTR,#(S M,#DR-E]L86(N>&ULS9QO;]LV$,;?%^AWN'EO-J"R8V=%4D>Z>NT?^G<+(5HX_K.<1/! A M*6]Y&@Q6E)3K!+O]_[Z='47S,C<]]395Z]6 MD)61="B3_5<\2$ZA18-0&J&_\_(P3^_R^@/OL-]=R[#S7A?,SHX_(=&5VH+$ MPU#PB%04UH>3ZITL/MXL5#Q9QX2%)%/^ILV#+&HFR'VJJME+)"4)NE/^T L) MU8 ,](:G-W2'/ZIOOHZXPOUT(F/A!_%VO4B?(B[RG8F)DXXAJ;?=D(X[%<&6 MEB^"7$=M[O&?1?0"KEZW1>PEBGGZO>!S8Q=9.6XX^#6:1,8V-4EJ2T\W8=Z7 MNWU>4Z&B,4$D7PJ%5YV7-O'S/E&&?W+M?X][C[5?2JOJ$B+)5=U^W9 \G2O, MU;_X(O*GMD@^26H)27/KW'#0!4F#$!*2WY1!2SL#V4"C12!MNW7#\9S%--Z, M5!GA1Y?J KS^G6QLL2Q);@G/:BN\(L@%UPI!)&S3"I"5@*0&J"+. #?8>A'D M^OV[(7W&@Z6>F['JWI;D[9R6 #8VSG>/N>"ZJX-$:2X,6MD93?PVBT1:]HJ# MX0T1E(?G+#Q3O\[4Y?%)',407-"*?E_,)$?4FIIC7ZG@8#'#S<7?PGVKA M4J[5(95' AJ[7P.]5DUC@#KVUY>A6BS1>YK>''\.M:4BK2*\SQJW"':'NU(8 MEW15"K9KX7+?J!7#$#S##\9(G(:A,B"S_ZXH(_UZXV 4:'44JBSQ/8'N(U J MBHM_IO\FWP!=":X9UCJF,1L&])_AI1GT!Z[H#UX<^@-;] =-H#_X?NB/5[PQ M])%L6*-?Z041_9':O!9COF+/ K^8_A*P-]@Q0?\8AH;\4\F&@-=E@ O0A7!A MQS90A;J="T3,D]^'K\6-X ^4!35OZY1IO 3@RXR9J'\2BX:^4;'#\#J T*XM2T"6&N#FXRY@FK60X$S$(5''NF_8 M3+]%2.LT[0;JGX+&,6$C/I\O678_4MK26I+<$K+55GA%D N\%8)(!&<58+N$ M,\4--EY$N6[W;CC?\8@&-*9L^DFMN 7U(UN639DM@5QA@I=%N"!VO0'DS&-(^M['+MY;2UMR@QP\W&G M98U1"VM1DXF#4H=$WGU-TTB_6RN:&DV[@3H6OG[4_&XSGW#K)?B3I)80-;?. M#0==X#0((9&9*4,J[4QE XT6D;3M%N>Z>;X.9LHMJ?,P@SFWY>NGT0@OC\&X MCN[J85]+\PHX#S,TU[?QFFK9/,;[>^=S(J9J:CX*OHIG:C&R\%G-!WE+)%I] MAZ_:%M\;ZOX>7X4L$NO9&V-Y(4@K058*Z3V^!FT8WN2K[05E!-;J)P>35-]- M3)^(J\F_(;]=^,L-\>HX!.Q+-)&97\-CF>PQ1BS@&S)@HMW&17''E=K2?UTH MVT73O[&C]OP/4$L#!!0 ( *U).E&ULU9I=<^(V%(;O=V;_@^K>M#,UYB-) Q.R0TFRPS1? M VS;Z82P9%]]6*:^1 MA&1JS$RWHFBQ6%22,1-:\KG!D+H2RS0B8>C:=X>?R&_K[EJD#QRH!I)2;4"1 M7^:,)ZUZM5ZOU:J7E8MMF0)JXY&$&FB19E2_B+!A@S1;YY>M^AGI/)#;+(H@ M0Y;"ME3.5HI-IH;\$/](,M&-% (XAQ6Y8X**F%%.!L[Q3Z0GX@KI<$[Z5J;1 MI@;U DEE$Y4S\5?+_AM9\^3].X)_6$>ALZ/MP%9C4XSE2/&*5!-T6VU$3A1L M:Y9[HD4CD]2:S6:4G1[F6-6F6ID^#:=KFNJI(<^C F M]O53OY?KT[ 7AHXH-U.]0M3I>G!EXZ#:Q %AZ%(*F:XBJXYN9#Q/01CWVA') MK3#,K'IB+%6:Y120K+RMJ8)Q.\ .XM!%L\Z^[V.@SZ<$,JL9?D,T2V<< A)M M9393.(J$R5K?XX&< )8&1 *)"V,3^,]SOUZ3W@QG&>=JX;[0&48-<64B7Z($ MF.VQ;M_80M6S(N&'SUV)#LH$$7?TE 'TTYL MZG><3HXUM"/*&]H&V%%Q+B15L0N';_?HY;\+FQ;1C"J,%\93G/6<>JQD6EB< M36^RT*A4":AV@.GC'!"0F6)2(6P\$I"Y1B]R9EU3;L_!&)2"Y'Z=]D&7F46< M3S5D+;\QGO5H[&(&BO(>#OWEK[ Z%M,!<7EQ'3#LL#6\P>;FDR&6\5A:>4UY M(>5].C;GWK%Y!O2*TWUR@Y=*IT+:$9>?UHYAA^W"&VSKN:$/$V83%>:1ID=3 M*]:6%UJQ7\?L9\^8X3)!JIE466D'6&'HRCE.\:NN3$Y$^(5092?Z!?L.\*5G M@.\8A\=Y.@)U&LUM7=G1;7MUG)J><1K292_!,K Q6R]5WP+M8)"R$SQH?(.S M4?4,9R=)L,AZ\X)K9:B=AK(P0-DQ%IIV"&O>(ZQ_+<*ZCPCK_R+T;6V^R:*+ M;Y_44"[$FP!NRSW!MVW9P?-GA9Y+);L4>U+/2KXPNQ7\%H)[,3S!N.?;L3SS MD^6SU(;R/]GL]-5%<01/..ZX=A3]V9>Q\TE' 3V%6UY37E)YGXZ-/YLO]MX6 M?YY*<>(Z;U]77D;[7ATG?S99Z0_',GSV4G6QZ6L]!?3W+@CC>$"WP[KCZL[$R@'AN+=;JHR$S M_.A+R7U=>;GM>W6<_-D]&2IJ'YX;K-*1//KG;D=47D([1AT>?_9'W!"[7<93 M*B9PRNW68FUY817[=Y34%-<.Q]5')AICB_SZ@X\9&A R'*2_!5VPZD M/ULAFW26.(L(S:RY]>,;)U(LT)<>88%GQ^]_V"ZYBO;J;L$JF,Q$ #MG . " M 0 !D-#H< !T:79C+3(P M,C,P.3(V+GAS9%!+ 0(4 Q0 ( *U).E>Y7>:;JP8 *1) 5 M " 5X@ !T:79C+3(P,C,P.3(V7VQA8BYX;6Q02P$"% ,4 " "M M23I7*+9J6>$$ 3+@ %0 @ $\)P =&EV8RTR,#(S,#DR ?-E]P&UL4$L%!@ % 4 0 $ % L $! end